Motor deficits and altered striatal gene expression in aphakia (ak) mice

Brain Research

Volumn 1185, Issue 1, 2007, Pages 283-292

  Singh, Bhupinder ^a   Wilson, Jean H ^a   Vasavada, Hema H ^a   Guo, Zhenchao ^b   Allore, Heather G ^b   Zeiss, Caroline J ^a  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aphakia; Denervation; Dopaminergic; Motor; Parkinson's; Striatum

Indexed keywords

ACETYLCHOLINESTERASE; GLUTAMATE RECEPTOR; MUSCARINIC RECEPTOR; PREPROENKEPHALIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APHAKIA; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DENERVATION; DOPAMINERGIC SYSTEM; GENE EXPRESSION REGULATION; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGE FACTORS; ANIMALS; APHAKIA; BEHAVIOR, ANIMAL; BODY WEIGHT; CORPUS STRIATUM; FEMALE; GENE EXPRESSION REGULATION; MALE; MICE; MICE, TRANSGENIC; MOVEMENT DISORDERS; NERVE TISSUE PROTEINS; NESTING BEHAVIOR; PSYCHOMOTOR PERFORMANCE; ROTAROD PERFORMANCE TEST;

GOSSYPIUM HIRSUTUM; MUS;

EID: 36448986022     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2007.09.006     Document Type: Article

References (88)

1. Araki T., Mikami T., Tanji H., Matsubara M., Imai Y., Mizugaki M., and Itoyama Y. Biochemical and immunohistological changes in the brain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse. Eur. J. Pharm. Sci. 12 (2001) 231-238
2. Bacci J.J., Kachidian P., Kerkerian-Le Goff L., and Salin P. Intralaminar thalamic nuclei lesions: widespread impact on dopamine denervation-mediated cellular defects in the rat basal ganglia. J. Neuropathol. Exp. Neurol. 63 (2004) 20-31
3. Backman C.M., Shan L., Zhang Y., Hoffer B.J., and Tomac A.C. Alterations in prodynorphin, proenkephalin, and GAD67 mRNA levels in the aged human putamen: correlation with Parkinson's disease. J. Neurosci. Res. 85 (2007) 798-804
4. Baquet Z.C., Gorski J.A., and Jones K.R. Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J. Neurosci. 24 (2004) 4250-4258
5. Barbeau A. The pathogenesis of Parkinson's disease: a new hypothesis. Can. Med. Assoc. J. 87 (1962) 802-807
6. Bertorelli R., and Consolo S. D1 and D2 dopaminergic regulation of acetylcholine release from striata of freely moving rats. J. Neurochem. 54 (1990) 2145-2148
7. Betarbet R., and Greenamyre J.T. Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP. Exp. Neurol. 189 (2004) 393-403
8. Bezard E., Dovero S., Prunier C., Ravenscroft P., Chalon S., Guilloteau D., Crossman A.R., Bioulac B., Brotchie J.M., and Gross C.E. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Neurosci. 21 (2001) 6853-6861
9. * nAChRs in mouse, monkey, and Parkinson's disease striatum. Mol. Pharmacol. 72 1 (2007) 52-61
10. Calabresi P., Pisani A., Mercuri N.B., and Bernardi G. The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia. Trends Neurosci. 19 (1996) 19-24
11. Calabresi P., Centonze D., Gubellini P., Pisani A., and Bernardi G. Acetylcholine-mediated modulation of striatal function. Trends Neurosci. 23 (2000) 120-126
12. Calabresi P., Picconi B., Parnetti L., and Di Filippo M. A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance. Lancet Neurol. 5 (2006) 974-983
13. Calon F., and Di Paolo T. Levodopa response motor complications-GABA receptors and preproenkephalin expression in human brain. Parkinsonism Relat. Disord. 8 (2002) 449-454
14. Cardozo-Pelaez F., Song S., Parthasarathy A., Hazzi C., Naidu K., and Sanchez-Ramos J. Oxidative DNA damage in the aging mouse brain. Mov. Disord. 14 (1999) 972-980
15. Chang B., Hawes N.L., Hurd R.E., Davisson M.T., Nusinowitz S., and Heckenlively J.R. Retinal degeneration mutants in the mouse. Vision Res. 42 4 (2002) 517-525
16. Chen H., Zhang S.M., Hernan M.A., Willett W.C., and Ascherio A. Weight loss in Parkinson's disease. Ann. Neurol. 53 (2003) 676-679
17. Chung S., Hedlund E., Hwang M., Kim D.W., Shin B.S., Hwang D.Y., Jung Kang U., Isacson O., and Kim K.S. The homeodomain transcription factor Pitx3 facilitates differentiation of mouse embryonic stem cells into AHD2-expressing dopaminergic neurons. Mol. Cell Neurosci. 28 (2005) 241-252
18. Cronise K., Finn D.A., Metten P., and Crabbe J.C. Scheduled access to ethanol results in motor impairment and tolerance in female C57BL/6J mice. Pharmacol. Biochem. Behav. 81 (2005) 943-953
19. DeBoer P., and Abercrombie E.D. Physiological release of striatal acetylcholine in vivo: modulation by D1 and D2 dopamine receptor subtypes. J. Pharmacol. Exp. Ther. 277 (1996) 775-783
20. Di Giovanni G., Di Matteo V., Pierucci M., Benigno A., and Esposito E. Serotonin involvement in the basal ganglia pathophysiology: could the 5-HT2C receptor be a new target for therapeutic strategies?. Curr. Med. Chem. 13 (2006) 3069-3081
21. Fernagut P.O., Chalon S., Diguet E., Guilloteau D., Tison F., and Jaber M. Motor behaviour deficits and their histopathological and functional correlates in the nigrostriatal system of dopamine transporter knockout mice. Neuroscience 116 (2003) 1123-1130
22. Fetsko L.A., Xu R., and Wang Y. Effects of age and dopamine D2L receptor-deficiency on motor and learning functions. Neurobiol. Aging 26 (2005) 521-530
23. Fleming S.M., Salcedo J., Fernagut P.O., Rockenstein E., Masliah E., Levine M.S., and Chesselet M.F. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J. Neurosci. 24 (2004) 9434-9440
24. Fowler S.C., Zarcone T.J., Vorontsova E., and Chen R. Motor and associative deficits in D2 dopamine receptor knockout mice. Int. J. Dev. Neurosci. 20 (2002) 309-321
25. Guigoni C., Aubert I., Li Q., Gurevich V.V., Benovic J.L., Ferry S., Mach U., Stark H., Leriche L., Hakansson K., Bioulac B.H., Gross C.E., Sokoloff P., Fisone G., Gurevich E.V., Bloch B., and Bezard E. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Parkinsonism Relat. Disord. 11 Suppl 1 (2005) S25-S29
26. Guillin O., Diaz J., Carroll P., Griffon N., Schwartz J.C., and Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 411 6833 (2001) 86-89
27. Hofele K., Sedelis M., Auburger G.W., Morgan S., Huston J.P., and Schwarting R.K. Evidence for a dissociation between MPTP toxicity and tyrosinase activity based on congenic mouse strain susceptibility. Exp. Neurol. 168 (2001) 116-122
28. Hurley M.J., and Jenner P. What has been learnt from study of dopamine receptors in Parkinson's disease?. Pharmacol. Ther. 111 (2006) 715-728
29. Hwang D.Y., Ardayfio P., Kang U.J., Semina E.V., and Kim K.S. Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. Brain Res. Mol. Brain Res. 114 (2003) 123-131
30. Hwang D.Y., Fleming S.M., Ardayfio P., Moran-Gates T., Kim H., Tarazi F.I., Chesselet M.F., and Kim K.S. 3,4-Dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson's disease. J. Neurosci. 25 (2005) 2132-2137
31. Iancu R., Mohapel P., Brundin P., and Paul G. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav. Brain Res. 162 (2005) 1-10
32. Jenner P. Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. J. Neurol. 247 Suppl 2 (2000) II43-II50
33. Johnson B.J., and Bruno J.P. Dopaminergic modulation of striatal acetylcholine release in rats depleted of dopamine as neonates. Neuropharmacology 34 (1995) 191-203
34. Joyce J.N. Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. III. Results in Parkinson's disease cases. Brain Res. 600 (1993) 156-160
35. Joyce J.N., Der T.C., Renish L., Osredkar T., Hagner D., Reploge M., Sakakibara S., and Ueda S. Loss of D3 receptors in the zitter mutant rat is not reversed by l-dopa treatment. Exp. Neurol. 187 (2004) 178-189
36. Kashani A., Betancur C., Giros B., Hirsch E., and El Mestikawy S. Altered expression of vesicular glutamate transporters VGLUT1 and VGLUT2 in Parkinson's disease. Neurobiol. Aging 28 (2007) 568-578
37. Kayadjanian N., Schofield W.N., Andren J., Sirinathsinghji D.J., and Besson M.J. Cortical and nigral deafferentation and striatal cholinergic markers in the rat dorsal striatum: different effects on the expression of mRNAs encoding choline acetyltransferase and muscarinic m1 and m4 receptors. Eur. J. Neurosci. 11 (1999) 3659-36608
38. Kim Y.J., Ichise M., Ballinger J.R., Vines D., Erami S.S., Tatschida T., and Lang A.E. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov. Disord. 17 (2002) 303-312
39. Kulak J.M., McIntosh J.M., and Quik M. Loss of nicotinic receptors in monkey striatum after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment is due to a decline in alpha-conotoxin MII sites. Mol. Pharmacol. 61 (2002) 230-238
40. Kunig G., Leenders K.L., Martin-Solch C., Missimer J., Magyar S., and Schultz W. Reduced reward processing in the brains of parkinsonian patients. Neuroreport 11 (2000) 3681-3687
41. Lehmann J., and Langer S.Z. The striatal cholinergic interneuron: synaptic target of dopaminergic terminals?. Neuroscience 10 (1983) 1105-1120
42. L'Honore A., Coulon V., Marcil A., Lebel M., Lafrance-Vanasse J., Gage P., Camper S., and Drouin J. Sequential expression and redundancy of Pitx2 and Pitx3 genes during muscle development. Dev. Biol. 307 2 (2007) 421-433
43. Linazasoro G. Pathophysiology of motor complications in Parkinson's disease: postsynaptic mechanisms are crucial. Arch. Neurol. 64 (2007) 137-140
44. Lindefors N., and Ungerstedt U. Bilateral regulation of glutamate tissue and extracellular levels in caudate-putamen by midbrain dopamine neurons. Neurosci. Lett. 115 (1990) 248-252
45. MacKenzie R.G., Stachowiak M.K., and Zigmond M.J. Dopaminergic inhibition of striatal acetylcholine release after 6-hydroxydopamine. Eur. J. Pharmacol. 168 (1989) 43-52
46. Markus H.S., Cox M., and Tomkins A.M. Raised resting energy expenditure in Parkinson's disease and its relationship to muscle rigidity. Clin. Sci. (Lond) 83 (1992) 199-204
47. Martorana A., Fusco F.R., D'Angelo V., Sancesario G., and Bernardi G. Enkephalin, neurotensin, and substance P immunoreactivity neurones of the rat GP following 6-hydroxydopamine lesion of the substantia nigra. Exp. Neurol. 183 (2003) 311-319
48. Matsuura K., Kabuto H., Makino H., and Ogawa N. Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J. Neurosci. Methods 73 (1997) 45-48
49. McCallum S.E., Parameswaran N., Bordia T., McIntosh J.M., Grady S.R., and Quik M. Decrease in alpha3*/alpha6* nicotinic receptors but not nicotine-evoked dopamine release in monkey brain after nigrostriatal damage. Mol. Pharmacol. 68 (2005) 737-746
50. McDonald W.M., Richard I.H., and DeLong M.R. Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol. Psychiatry 54 (2003) 363-375
51. Meissner W., Dovero S., Bioulac B., Gross C.E., and Bezard E. Compensatory regulation of striatal neuropeptide gene expression occurs before changes in metabolic activity of basal ganglia nuclei. Neurobiol. Dis. 13 (2003) 46-54
52. Morissette M., Goulet M., Grondin R., Blanchet P., Bedard P.J., DiPaolo T., and Levesque D. Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies. Eur. J. Neurosci. 10 (1998) 2565-2573
53. Morissette M., Grondin R., Goulet M., Bedard P.J., and Di Paolo T. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists. J. Neurochem. 72 (1999) 682-692
54. Muller J., Wenning G.K., Verny M., McKee A., Chaudhuri K.R., Jellinger K., Poewe W., and Litvan I. Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. Arch. Neurol. 58 (2001) 259-264
55. Muller A., Mungersdorf M., Reichmann H., Strehle G., and Hummel T. Olfactory function in parkinsonian syndromes. J. Clin. Neurosci. 9 (2002) 521-524
56. Nisenbaum L.K., Crowley W.R., and Kitai S.T. Partial striatal dopamine depletion differentially affects striatal substance P and enkephalin messenger RNA expression. Brain Res. Mol. Brain Res. 37 (1996) 209-216
57. Nunes I., Tovmasian L.T., Silva R.M., Burke R.E., and Goff S.P. Pitx3 is required for development of substantia nigra dopaminergic neurons. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 4245-4250
58. Ogawa N., Hirose Y., Ohara S., Ono T., and Watanabe Y. A simple quantitative bradykinesia test in MPTP-treated mice. Res. Commun. Chem. Pathol. Pharmacol. 50 (1985) 435-441
59. Olanow C.W., Obeso J.A., and Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 5 (2006) 677-687
60. Ott B.R., and Lannon M.C. Exacerbation of parkinsonism by tacrine. Clin. Neuropharmacol. 15 (1992) 322-325
61. Pfaffl M.W., Horgan G.W., and Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 30 9 (2002) e36
62. Piggott M.A., Marshall E.F., Thomas N., Lloyd S., Court J.A., Jaros E., Burn D., Johnson M., Perry R.H., McKeith I.G., Ballard C., and Perry E.K. Striatal dopaminergic markers in dementia with lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain 122 Pt 8 (1999) 1449-1468
63. Quik M., Police S., He L., Di Monte D.A., and Langston J.W. Expression of D(3) receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment. Neuroscience 98 (2000) 263-273
64. Quik M., Police S., Langston J.W., and Di Monte D.A. Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not l-DOPA-induced dyskinesias in the squirrel monkey. Neuroscience 113 (2002) 213-220
65. Quik M., Sum J.D., Whiteaker P., McCallum S.E., Marks M.J., Musachio J., McIntosh J.M., Collins A.C., and Grady S.R. Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice. Mol. Pharmacol. 63 (2003) 1169-1179
66. Quik M., Vailati S., Bordia T., Kulak J.M., Fan H., McIntosh J.M., Clementi F., and Gotti C. Subunit composition of nicotinic receptors in monkey striatum: effect of treatments with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine or l-DOPA. Mol. Pharmacol. 67 (2005) 32-41
67. Ramakers C., Ruijter J.M., Deprez R.H., and Moorman A.F. Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci. Lett. 339 1 (2003) 62-66
68. Rieger D.K., Reichenberger E., McLean W., Sidow A., and Olsen B.R. A double-deletion mutation in the Pitx3 gene causes arrested lens development in aphakia mice. Genomics 72 (2001) 61-72
69. Robelet S., Melon C., Guillet B., Salin P., and Kerkerian-Le Goff L. Chronic l-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease. Eur. J. Neurosci. 20 (2004) 1255-1266
70. Ryoo H.L., Pierrotti D., and Joyce J.N. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease. Mov. Disord. 13 (1998) 788-797
71. Salamone J.D., Correa M., Carlson B.B., Wisniecki A., Mayorga A.J., Nisenbaum E., Nisenbaum L., and Felder C. Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents implications for cholinergic involvement in parkinsonism. Life Sci. 68 (2001) 2579-2584
72. Schefe J.H., Lehmann K.E., Buschmann I.R., Unger T., and Heiko F.-K. Quantitative real-time RT-PCR data analysis: current concepts and novel "gene expression's Ct difference" formula. J. Mol. Med. 84 (2006) 901-910
73. Sedelis M., Hofele K., Auburger G.W., Morgan S., Huston J.P., and Schwarting R.K. MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav. Genet. 30 (2000) 171-182
74. Sedelis M., Schwarting R.K., and Huston J.P. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav. Brain Res. 125 (2001) 109-125
75. Semina E.V., Reiter R.S., and Murray J.C. Isolation of a new homeobox gene belonging to the Pitx/Rieg family: expression during lens development and mapping to the aphakia region on mouse chromosome 19. Hum. Mol. Genet. 6 (1997) 2109-2116
76. Semina E.V., Murray J.C., Reiter R., Hrstka R.F., and Graw J. Deletion in the promoter region and altered expression of Pitx3 homeobox gene in aphakia mice. Hum. Mol. Genet. 9 (2000) 1575-1585
77. Smidt M.P., van Schaick H.S., Lanctot C., Tremblay J.J., Cox J.J., van der Kleij A.A., Wolterink G., Drouin J., and Burbach J.P. A homeodomain gene Ptx3 has highly restricted brain expression in mesencephalic dopaminergic neurons. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 13305-13310
78. Smidt M.P., Smits S.M., Bouwmeester H., Hamers F.P., van der Linden A.J., Hellemons A.J., Graw J., and Burbach J.P. Early developmental failure of substantia nigra dopamine neurons in mice lacking the homeodomain gene Pitx3. Development 131 (2004) 1145-1155
79. Smits S.M., Mathon D.S., Burbach J.P., Ramakers G.M., and Smidt M.P. Molecular and cellular alterations in the Pitx3-deficient midbrain dopaminergic system. Mol. Cell Neurosci. 30 (2005) 352-363
80. Szczypka M.S., Kwok K., Brot M.D., Marck B.T., Matsumoto A.M., Donahue B.A., and Palmiter R.D. Dopamine production in the caudate putamen restores feeding in dopamine-deficient mice. Neuron 30 (2001) 819-828
81. Thobois S., Vingerhoets F., Fraix V., Xie-Brustolin J., Mollion H., Costes N., Mertens P., Benabid A.L., Pollak P., and Broussolle E. Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study. Arch. Neurol. 61 (2004) 1705-1709
82. Upchurch M., and Schallert T. A behavior analysis of the offspring of "haloperidol-sensitive" and "haloperidol-resistant" gerbils. Behav. Neural Biol. 39 (1983) 221-228
83. van den Munckhof P., Luk K.C., Ste-Marie L., Montgomery J., Blanchet P.J., Sadikot A.F., and Drouin J. Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons. Development 130 (2003) 2535-2542
84. van den Munckhof P., Gilbert F., Chamberland M., Levesque D., and Drouin J. Striatal neuroadaptation and rescue of locomotor deficit by l-dopa in aphakia mice, a model of Parkinson's disease. J. Neurochem. 96 (2006) 160-170
85. Wade T.V., Rothblat D.S., and Schneider J.S. Changes in striatal dopamine D3 receptor regulation during expression of and recovery from MPTP-induced parkinsonism. Brain Res. 905 (2001) 111-119
86. Wonnacott S., Kaiser S., Mogg A., Soliakov L., and Jones I.W. Presynaptic nicotinic receptors modulating dopamine release in the rat striatum. Eur. J. Pharmacol. 393 (2000) 51-58
87. Zhou F.M., Wilson C., and Dani J.A. Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems. Neuroscientist 9 (2003) 23-36
88. Zoli M., Moretti M., Zanardi A., McIntosh J.M., Clementi F., and Gotti C. Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum. J. Neurosci. 22 (2002) 8785-8789